Beijing Yuanfang Tongda Pharmaceutical Technology Co., Ltd.

To study the pharmacokinetic characteristics of the test preparation (zinc acetate tablets, 50 mg (calculated as Zn), licensed by Beijing Yuanfang Tongda Pharmaceutical Technology Co., Ltd.) and the reference preparation (zinc acetate tablets, 50 mg (calculated as Zn), trade name NOBELZIN, licensed by Nobel Pharma Co., Ltd.) in healthy research participants after a single oral administration in the fasting and fed state, to compare the bioequivalence of the test preparation and the reference preparation, and to study the safety of the drug in healthy research participants.

Primary objective: To compare the differences in the extent and rate of absorption of spironolactone oral suspension (specification: 118 mL: 0.59 g) provided by Beijing Yuanfang Tongda Pharmaceutical Technology Co., Ltd. and spironolactone oral suspension (trade name: CAROSPIR®; specification: 25 mg/5 mL) licensed by Cmp Development Llc in healthy Chinese people under fasting conditions. Secondary objective: To evaluate the safety of spironolactone oral suspension (specification: 118 mL: 0.59 g) provided by Beijing Yuanfang Tongda Pharmaceutical Technology Co., Ltd. and spironolactone oral suspension (trade name: CAROSPIR®; specification: 25 mg/5 mL) licensed by Cmp Development Llc under fasting conditions in healthy study participants

A single-center, randomized, open-label, four-period completely repeated crossover design and single-dose design were used to compare the differences in absorption extent and rate between the compound glycyrrhizic acid tablets (specifications: each tablet contains 35 mg monoammonium glycyrrhizic acid (25 mg glycyrrhizic acid), 25 mg glycine, and 25 mg DL-methionine) provided by Beijing Yuanfangtongda Pharmaceutical Technology Co., Ltd. and the compound glycyrrhizic acid tablets (specifications: each tablet contains 35 mg monoammonium glycyrrhizic acid (25 mg glycyrrhizic acid), 25 mg glycine, and 25 mg DL-methionine; trade name: Minophagen®/Stronger Neo-Minophagen C®) certified by Minophagen Pharmaceutical Co., Ltd. under fasting and postprandial administration conditions in healthy people, and to evaluate the safety and tolerability of the compound glycyrrhizic acid tablets provided by Beijing Yuanfangtongda Pharmaceutical Technology Co., Ltd. and the compound glycyrrhizic acid tablets certified by Minophagen Pharmaceutical Co., Ltd.